Bristol Myers, yielding to FDA pressure, pulls Opdivo in post-Nexavar liver cancer | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  27804 of 28050  at  7/29/2021 1:55:51 PM  by


Bristol Myers, yielding to FDA pressure, pulls Opdivo in post-Nexavar liver cancer

by Angus Liu | Jul 26, 2021

Amid a regulatory campaign targeting immuno-oncology agents, Bristol Myers Squibb figured its probably futile to keep fighting the FDA on Opdivos shaky use in previously treated liver cancer.

On Friday, Bristol Myers said its voluntarily withdrawing Opdivos approval in hepatocellular carcinoma patients who previously received Bayers standard-of-care Nexavar.

The decision came about three months after an independent FDA advisory committee voted 5-4 to remove the Opdivo accelerated approval, which the company scored back in 2017 based on tumor shrinkage data. The FDA convened its April meeting to help with an industry-wide review of accelerated approvals for checkpoint inhibitors that didnt pass muster in confirmatory trials.

For Opdivo, concerns about the meds use in second-line liver cancer use cropped up after the drug failed a confirmatory trial in the first-line setting. In the CheckMate-459 trial, the PD-1 inhibitor failed to significantly prolong the time newly diagnosed liver cancer patients lived compared with Nexavar.

In a Friday statement, Bristol Myers head of oncology development, Jonathan Cheng, said the company is disappointed by the position the advisory committee and the FDA have taken for Opdivos use in post-Nexavar liver cancer. Single-agent Opdivo is currently the most used therapy in the disease setting, he pointed out.

Since Opdivos conditional nod in 2017, Roche has won FDA full approval for its pairing of PD-L1 inhibitor Tecentriq and Avastin in newly diagnosed patients last year. This means many patients can get a PD-1/L1 drug upfront. Still, as the FDA external advisers acknowledged, some patients may not be able to tolerate the Tecentriq-Avastin regimen in the front line, leaving a need for immunotherapy in the second line.

But the door isnt completely closed for Opdivo in second-line liver cancer. The drugs combination with BMSs own CTLA-4 inhibitor Yervoy also has an accelerated approval in the setting, and its not affected by the Opdivo monotherapy withdrawal. A phase 3 trial dubbed CheckMate-9DW is now aiming to confirm the benefits of the dual immunotherapy.

Meanwhile, Merck & Co.s rival PD-1 inhibitor Keytruda is hoping to prove its case in post-Nexavar liver cancer. The Merck drug narrowly missed the life extension goal in the Keynote-240 trial when compared with placebo in the second-line setting.

While the FDA expert panel also voted to keep Keytrudas conditional nod in place, the group is looking to readout from the Keynote-394 studywhich is conducted in Asian patientsto validate the drugs benefits. The study bears an estimated primary completion date at the end of June, according to Merck has yet to communicate its results.

BMS move to pull Opdivos approval in second-line liver cancer comes as the FDA re-evaluates accelerated approvals for PD-1/L1 medicines that have failed in confirmatory trials. Late last year, the company was the first to respond to the agencys industry-wide review, walking away from an Opdivo conditional nod in third-line small cell lung cancer.

Merck has also abandoned Keytrudas U.S. indication in third-line SCLC. And after a negative opinion from the FDA advisory committee, the New Jersey pharma giant a few weeks ago said it would pull Keytrudas U.S. use in third-line, PD-L1-positive stomach cancer.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1  
   Views: 0 []
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Financial Market Data provided by